JP2010507464A - 液体節約型カスケード血液濾過法 - Google Patents
液体節約型カスケード血液濾過法 Download PDFInfo
- Publication number
- JP2010507464A JP2010507464A JP2009534821A JP2009534821A JP2010507464A JP 2010507464 A JP2010507464 A JP 2010507464A JP 2009534821 A JP2009534821 A JP 2009534821A JP 2009534821 A JP2009534821 A JP 2009534821A JP 2010507464 A JP2010507464 A JP 2010507464A
- Authority
- JP
- Japan
- Prior art keywords
- reservoir
- liquid
- effluent
- primary
- molecular weight
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 238000002615 hemofiltration Methods 0.000 title description 22
- 239000007788 liquid Substances 0.000 claims abstract description 118
- 238000000746 purification Methods 0.000 claims abstract description 112
- 210000004369 blood Anatomy 0.000 claims abstract description 64
- 239000008280 blood Substances 0.000 claims abstract description 63
- 239000012530 fluid Substances 0.000 claims abstract description 57
- 238000000034 method Methods 0.000 claims abstract description 49
- 239000003053 toxin Substances 0.000 claims abstract description 47
- 231100000765 toxin Toxicity 0.000 claims abstract description 47
- 108700012359 toxins Proteins 0.000 claims abstract description 47
- 102000009027 Albumins Human genes 0.000 claims abstract description 31
- 108010088751 Albumins Proteins 0.000 claims abstract description 31
- 238000001179 sorption measurement Methods 0.000 claims abstract description 24
- 238000000502 dialysis Methods 0.000 claims abstract description 21
- 238000001802 infusion Methods 0.000 claims abstract description 12
- 238000002347 injection Methods 0.000 claims abstract description 8
- 239000007924 injection Substances 0.000 claims abstract description 8
- 210000002381 plasma Anatomy 0.000 claims description 21
- 238000005086 pumping Methods 0.000 claims description 19
- 230000024033 toxin binding Effects 0.000 claims description 19
- 238000009826 distribution Methods 0.000 claims description 16
- 238000007873 sieving Methods 0.000 claims description 12
- 239000012510 hollow fiber Substances 0.000 claims description 11
- 102000004169 proteins and genes Human genes 0.000 claims description 11
- 108090000623 proteins and genes Proteins 0.000 claims description 11
- 239000000126 substance Substances 0.000 claims description 8
- 230000001225 therapeutic effect Effects 0.000 claims description 8
- 210000004185 liver Anatomy 0.000 claims description 7
- 230000000717 retained effect Effects 0.000 claims description 6
- 108060003951 Immunoglobulin Proteins 0.000 claims description 5
- 108091008324 binding proteins Proteins 0.000 claims description 5
- 210000001124 body fluid Anatomy 0.000 claims description 5
- 239000010839 body fluid Substances 0.000 claims description 5
- 102000018358 immunoglobulin Human genes 0.000 claims description 5
- 229940072221 immunoglobulins Drugs 0.000 claims description 5
- 210000003734 kidney Anatomy 0.000 claims description 5
- 102000019034 Chemokines Human genes 0.000 claims description 4
- 108010012236 Chemokines Proteins 0.000 claims description 4
- 102000004127 Cytokines Human genes 0.000 claims description 4
- 108090000695 Cytokines Proteins 0.000 claims description 4
- 238000011160 research Methods 0.000 claims description 4
- 210000002966 serum Anatomy 0.000 claims description 4
- 206010003445 Ascites Diseases 0.000 claims description 3
- 230000005526 G1 to G0 transition Effects 0.000 claims description 3
- 210000001175 cerebrospinal fluid Anatomy 0.000 claims description 3
- 238000000605 extraction Methods 0.000 claims description 3
- 239000002955 immunomodulating agent Substances 0.000 claims description 3
- 229940121354 immunomodulator Drugs 0.000 claims description 3
- 230000000977 initiatory effect Effects 0.000 claims description 3
- 210000005166 vasculature Anatomy 0.000 claims description 3
- 238000004891 communication Methods 0.000 claims description 2
- 239000012141 concentrate Substances 0.000 claims description 2
- 238000011049 filling Methods 0.000 claims description 2
- 102000014914 Carrier Proteins Human genes 0.000 claims 2
- 239000002699 waste material Substances 0.000 abstract description 5
- 239000000306 component Substances 0.000 description 67
- 238000000108 ultra-filtration Methods 0.000 description 28
- 239000012528 membrane Substances 0.000 description 20
- 238000001914 filtration Methods 0.000 description 15
- 238000010586 diagram Methods 0.000 description 12
- 239000003463 adsorbent Substances 0.000 description 11
- 238000010790 dilution Methods 0.000 description 11
- 239000012895 dilution Substances 0.000 description 11
- 238000011282 treatment Methods 0.000 description 11
- 239000000243 solution Substances 0.000 description 9
- QGZKDVFQNNGYKY-UHFFFAOYSA-N Ammonia Chemical compound N QGZKDVFQNNGYKY-UHFFFAOYSA-N 0.000 description 8
- DDRJAANPRJIHGJ-UHFFFAOYSA-N creatinine Chemical compound CN1CC(=O)NC1=N DDRJAANPRJIHGJ-UHFFFAOYSA-N 0.000 description 8
- 208000010718 Multiple Organ Failure Diseases 0.000 description 7
- XSQUKJJJFZCRTK-UHFFFAOYSA-N Urea Chemical compound NC(N)=O XSQUKJJJFZCRTK-UHFFFAOYSA-N 0.000 description 7
- 239000003814 drug Substances 0.000 description 7
- 208000029744 multiple organ dysfunction syndrome Diseases 0.000 description 7
- MWUXSHHQAYIFBG-UHFFFAOYSA-N Nitric oxide Chemical compound O=[N] MWUXSHHQAYIFBG-UHFFFAOYSA-N 0.000 description 6
- 229940079593 drug Drugs 0.000 description 6
- 230000002757 inflammatory effect Effects 0.000 description 6
- 235000015097 nutrients Nutrition 0.000 description 6
- OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical compound [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 description 5
- 239000003242 anti bacterial agent Substances 0.000 description 5
- 229940088710 antibiotic agent Drugs 0.000 description 5
- 210000004027 cell Anatomy 0.000 description 5
- 201000010099 disease Diseases 0.000 description 5
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 5
- 239000005556 hormone Substances 0.000 description 5
- 229940088597 hormone Drugs 0.000 description 5
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 5
- BPYKTIZUTYGOLE-IFADSCNNSA-N Bilirubin Chemical compound N1C(=O)C(C)=C(C=C)\C1=C\C1=C(C)C(CCC(O)=O)=C(CC2=C(C(C)=C(\C=C/3C(=C(C=C)C(=O)N\3)C)N2)CCC(O)=O)N1 BPYKTIZUTYGOLE-IFADSCNNSA-N 0.000 description 4
- 208000001647 Renal Insufficiency Diseases 0.000 description 4
- 206010040047 Sepsis Diseases 0.000 description 4
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 4
- 229910021529 ammonia Inorganic materials 0.000 description 4
- 230000009286 beneficial effect Effects 0.000 description 4
- 230000008901 benefit Effects 0.000 description 4
- 239000012503 blood component Substances 0.000 description 4
- 239000004202 carbamide Substances 0.000 description 4
- 238000005119 centrifugation Methods 0.000 description 4
- 229940109239 creatinine Drugs 0.000 description 4
- 230000006870 function Effects 0.000 description 4
- 201000006370 kidney failure Diseases 0.000 description 4
- 238000002483 medication Methods 0.000 description 4
- 239000011148 porous material Substances 0.000 description 4
- 238000002560 therapeutic procedure Methods 0.000 description 4
- ISWSIDIOOBJBQZ-UHFFFAOYSA-N Phenol Chemical compound OC1=CC=CC=C1 ISWSIDIOOBJBQZ-UHFFFAOYSA-N 0.000 description 3
- 230000009471 action Effects 0.000 description 3
- 102000023732 binding proteins Human genes 0.000 description 3
- 230000008859 change Effects 0.000 description 3
- 239000003792 electrolyte Substances 0.000 description 3
- 210000001035 gastrointestinal tract Anatomy 0.000 description 3
- 238000004519 manufacturing process Methods 0.000 description 3
- 239000000463 material Substances 0.000 description 3
- 210000000056 organ Anatomy 0.000 description 3
- 239000011347 resin Substances 0.000 description 3
- 229920005989 resin Polymers 0.000 description 3
- 150000003384 small molecules Chemical class 0.000 description 3
- 208000011580 syndromic disease Diseases 0.000 description 3
- HVAUUPRFYPCOCA-AREMUKBSSA-N 2-O-acetyl-1-O-hexadecyl-sn-glycero-3-phosphocholine Chemical compound CCCCCCCCCCCCCCCCOC[C@@H](OC(C)=O)COP([O-])(=O)OCC[N+](C)(C)C HVAUUPRFYPCOCA-AREMUKBSSA-N 0.000 description 2
- 208000007788 Acute Liver Failure Diseases 0.000 description 2
- 206010000804 Acute hepatic failure Diseases 0.000 description 2
- 206010001052 Acute respiratory distress syndrome Diseases 0.000 description 2
- 206010007559 Cardiac failure congestive Diseases 0.000 description 2
- 208000010334 End Stage Liver Disease Diseases 0.000 description 2
- 206010018910 Haemolysis Diseases 0.000 description 2
- 206010019280 Heart failures Diseases 0.000 description 2
- 206010019663 Hepatic failure Diseases 0.000 description 2
- 208000031226 Hyperlipidaemia Diseases 0.000 description 2
- 208000020858 L1 syndrome Diseases 0.000 description 2
- 201000002961 MASA syndrome Diseases 0.000 description 2
- 108010003541 Platelet Activating Factor Proteins 0.000 description 2
- 206010040070 Septic Shock Diseases 0.000 description 2
- 238000009825 accumulation Methods 0.000 description 2
- 230000001154 acute effect Effects 0.000 description 2
- 150000001413 amino acids Chemical class 0.000 description 2
- 239000003613 bile acid Substances 0.000 description 2
- 230000027455 binding Effects 0.000 description 2
- 230000017531 blood circulation Effects 0.000 description 2
- 239000003610 charcoal Substances 0.000 description 2
- 208000011444 chronic liver failure Diseases 0.000 description 2
- 238000005352 clarification Methods 0.000 description 2
- -1 dialysate Substances 0.000 description 2
- 239000002934 diuretic Substances 0.000 description 2
- 229940030606 diuretics Drugs 0.000 description 2
- 239000008151 electrolyte solution Substances 0.000 description 2
- 239000012634 fragment Substances 0.000 description 2
- 238000001631 haemodialysis Methods 0.000 description 2
- 230000000322 hemodialysis Effects 0.000 description 2
- 230000008588 hemolysis Effects 0.000 description 2
- 201000011200 hepatorenal syndrome Diseases 0.000 description 2
- 208000015181 infectious disease Diseases 0.000 description 2
- 239000004615 ingredient Substances 0.000 description 2
- 208000014674 injury Diseases 0.000 description 2
- 150000002500 ions Chemical class 0.000 description 2
- 208000007903 liver failure Diseases 0.000 description 2
- 231100000835 liver failure Toxicity 0.000 description 2
- 229920002521 macromolecule Polymers 0.000 description 2
- 230000004060 metabolic process Effects 0.000 description 2
- 239000000203 mixture Substances 0.000 description 2
- 230000004048 modification Effects 0.000 description 2
- 238000012986 modification Methods 0.000 description 2
- 229920000642 polymer Polymers 0.000 description 2
- 230000008569 process Effects 0.000 description 2
- 206010039073 rheumatoid arthritis Diseases 0.000 description 2
- 229940125723 sedative agent Drugs 0.000 description 2
- 239000000932 sedative agent Substances 0.000 description 2
- 230000036303 septic shock Effects 0.000 description 2
- 239000000377 silicon dioxide Substances 0.000 description 2
- 241000894007 species Species 0.000 description 2
- 230000009885 systemic effect Effects 0.000 description 2
- 230000008733 trauma Effects 0.000 description 2
- 238000011144 upstream manufacturing Methods 0.000 description 2
- NWUYHJFMYQTDRP-UHFFFAOYSA-N 1,2-bis(ethenyl)benzene;1-ethenyl-2-ethylbenzene;styrene Chemical compound C=CC1=CC=CC=C1.CCC1=CC=CC=C1C=C.C=CC1=CC=CC=C1C=C NWUYHJFMYQTDRP-UHFFFAOYSA-N 0.000 description 1
- 208000009304 Acute Kidney Injury Diseases 0.000 description 1
- 231100000699 Bacterial toxin Toxicity 0.000 description 1
- 208000027205 Congenital disease Diseases 0.000 description 1
- 208000029767 Congenital, Hereditary, and Neonatal Diseases and Abnormalities Diseases 0.000 description 1
- 206010015150 Erythema Diseases 0.000 description 1
- 229920001917 Ficoll Polymers 0.000 description 1
- 208000024869 Goodpasture syndrome Diseases 0.000 description 1
- 206010021113 Hypothermia Diseases 0.000 description 1
- 206010061218 Inflammation Diseases 0.000 description 1
- 102000008070 Interferon-gamma Human genes 0.000 description 1
- 108010074328 Interferon-gamma Proteins 0.000 description 1
- 108010002352 Interleukin-1 Proteins 0.000 description 1
- 108090000171 Interleukin-18 Proteins 0.000 description 1
- 108090001005 Interleukin-6 Proteins 0.000 description 1
- 108010063738 Interleukins Proteins 0.000 description 1
- 102000015696 Interleukins Human genes 0.000 description 1
- LSDPWZHWYPCBBB-UHFFFAOYSA-N Methanethiol Chemical compound SC LSDPWZHWYPCBBB-UHFFFAOYSA-N 0.000 description 1
- 208000034486 Multi-organ failure Diseases 0.000 description 1
- 239000004695 Polyether sulfone Substances 0.000 description 1
- 208000033626 Renal failure acute Diseases 0.000 description 1
- 101710087249 Small toxin Proteins 0.000 description 1
- 108060008682 Tumor Necrosis Factor Proteins 0.000 description 1
- 208000016025 Waldenstroem macroglobulinemia Diseases 0.000 description 1
- 208000033559 Waldenström macroglobulinemia Diseases 0.000 description 1
- 201000011040 acute kidney failure Diseases 0.000 description 1
- 208000012998 acute renal failure Diseases 0.000 description 1
- 229940035676 analgesics Drugs 0.000 description 1
- 238000005349 anion exchange Methods 0.000 description 1
- 239000003957 anion exchange resin Substances 0.000 description 1
- 239000005557 antagonist Substances 0.000 description 1
- 239000000730 antalgic agent Substances 0.000 description 1
- 230000003373 anti-fouling effect Effects 0.000 description 1
- 230000003110 anti-inflammatory effect Effects 0.000 description 1
- 239000003146 anticoagulant agent Substances 0.000 description 1
- 229940127219 anticoagulant drug Drugs 0.000 description 1
- 239000003443 antiviral agent Substances 0.000 description 1
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 description 1
- 239000000688 bacterial toxin Substances 0.000 description 1
- 239000011324 bead Substances 0.000 description 1
- 230000000975 bioactive effect Effects 0.000 description 1
- 239000013060 biological fluid Substances 0.000 description 1
- 230000008827 biological function Effects 0.000 description 1
- 230000015572 biosynthetic process Effects 0.000 description 1
- 210000000601 blood cell Anatomy 0.000 description 1
- 230000023555 blood coagulation Effects 0.000 description 1
- 239000003114 blood coagulation factor Substances 0.000 description 1
- 230000036770 blood supply Effects 0.000 description 1
- 239000000496 cardiotonic agent Substances 0.000 description 1
- 239000003729 cation exchange resin Substances 0.000 description 1
- 230000001413 cellular effect Effects 0.000 description 1
- 229920002678 cellulose Polymers 0.000 description 1
- 239000001913 cellulose Substances 0.000 description 1
- 229920002301 cellulose acetate Polymers 0.000 description 1
- 238000006243 chemical reaction Methods 0.000 description 1
- 238000004587 chromatography analysis Methods 0.000 description 1
- 239000011248 coating agent Substances 0.000 description 1
- 238000000576 coating method Methods 0.000 description 1
- 150000001875 compounds Chemical class 0.000 description 1
- 238000011109 contamination Methods 0.000 description 1
- 230000008878 coupling Effects 0.000 description 1
- 238000010168 coupling process Methods 0.000 description 1
- 238000005859 coupling reaction Methods 0.000 description 1
- 230000001186 cumulative effect Effects 0.000 description 1
- 230000018044 dehydration Effects 0.000 description 1
- 238000006297 dehydration reaction Methods 0.000 description 1
- 230000002939 deleterious effect Effects 0.000 description 1
- 238000001784 detoxification Methods 0.000 description 1
- 238000011982 device technology Methods 0.000 description 1
- 230000000694 effects Effects 0.000 description 1
- 238000005516 engineering process Methods 0.000 description 1
- 231100000321 erythema Toxicity 0.000 description 1
- 210000003743 erythrocyte Anatomy 0.000 description 1
- 230000029142 excretion Effects 0.000 description 1
- 239000000706 filtrate Substances 0.000 description 1
- 230000004907 flux Effects 0.000 description 1
- 238000005194 fractionation Methods 0.000 description 1
- 239000004023 fresh frozen plasma Substances 0.000 description 1
- 239000007789 gas Substances 0.000 description 1
- 238000007429 general method Methods 0.000 description 1
- 239000008187 granular material Substances 0.000 description 1
- 230000005484 gravity Effects 0.000 description 1
- 239000000383 hazardous chemical Substances 0.000 description 1
- 210000003494 hepatocyte Anatomy 0.000 description 1
- 230000002631 hypothermal effect Effects 0.000 description 1
- 230000036512 infertility Effects 0.000 description 1
- 230000004054 inflammatory process Effects 0.000 description 1
- 230000028709 inflammatory response Effects 0.000 description 1
- 230000003993 interaction Effects 0.000 description 1
- 229960003130 interferon gamma Drugs 0.000 description 1
- 229940047122 interleukins Drugs 0.000 description 1
- 238000001990 intravenous administration Methods 0.000 description 1
- 239000003456 ion exchange resin Substances 0.000 description 1
- 229920003303 ion-exchange polymer Polymers 0.000 description 1
- 230000003907 kidney function Effects 0.000 description 1
- 150000002617 leukotrienes Chemical class 0.000 description 1
- GZQKNULLWNGMCW-PWQABINMSA-N lipid A (E. coli) Chemical compound O1[C@H](CO)[C@@H](OP(O)(O)=O)[C@H](OC(=O)C[C@@H](CCCCCCCCCCC)OC(=O)CCCCCCCCCCCCC)[C@@H](NC(=O)C[C@@H](CCCCCCCCCCC)OC(=O)CCCCCCCCCCC)[C@@H]1OC[C@@H]1[C@@H](O)[C@H](OC(=O)C[C@H](O)CCCCCCCCCCC)[C@@H](NC(=O)C[C@H](O)CCCCCCCCCCC)[C@@H](OP(O)(O)=O)O1 GZQKNULLWNGMCW-PWQABINMSA-N 0.000 description 1
- 230000003908 liver function Effects 0.000 description 1
- 210000004072 lung Anatomy 0.000 description 1
- 206010025135 lupus erythematosus Diseases 0.000 description 1
- 230000014759 maintenance of location Effects 0.000 description 1
- 230000002503 metabolic effect Effects 0.000 description 1
- 201000008383 nephritis Diseases 0.000 description 1
- 230000007935 neutral effect Effects 0.000 description 1
- 230000003204 osmotic effect Effects 0.000 description 1
- 239000001301 oxygen Substances 0.000 description 1
- 229910052760 oxygen Inorganic materials 0.000 description 1
- 238000006213 oxygenation reaction Methods 0.000 description 1
- 229940094443 oxytocics prostaglandins Drugs 0.000 description 1
- 239000002245 particle Substances 0.000 description 1
- 244000052769 pathogen Species 0.000 description 1
- 230000001717 pathogenic effect Effects 0.000 description 1
- 230000001575 pathological effect Effects 0.000 description 1
- 230000007310 pathophysiology Effects 0.000 description 1
- 239000012466 permeate Substances 0.000 description 1
- 231100000614 poison Toxicity 0.000 description 1
- 229920002492 poly(sulfone) Polymers 0.000 description 1
- 229920006393 polyether sulfone Polymers 0.000 description 1
- 239000002861 polymer material Substances 0.000 description 1
- 238000012545 processing Methods 0.000 description 1
- 230000002035 prolonged effect Effects 0.000 description 1
- 150000003180 prostaglandins Chemical class 0.000 description 1
- 230000004845 protein aggregation Effects 0.000 description 1
- 239000003642 reactive oxygen metabolite Substances 0.000 description 1
- 230000003134 recirculating effect Effects 0.000 description 1
- 230000002441 reversible effect Effects 0.000 description 1
- 150000003839 salts Chemical class 0.000 description 1
- 150000004666 short chain fatty acids Chemical class 0.000 description 1
- 235000021391 short chain fatty acids Nutrition 0.000 description 1
- 229940126586 small molecule drug Drugs 0.000 description 1
- 239000002689 soil Substances 0.000 description 1
- 230000001954 sterilising effect Effects 0.000 description 1
- 238000004659 sterilization and disinfection Methods 0.000 description 1
- 150000003431 steroids Chemical class 0.000 description 1
- 235000000346 sugar Nutrition 0.000 description 1
- 150000008163 sugars Chemical class 0.000 description 1
- 239000013589 supplement Substances 0.000 description 1
- 238000003786 synthesis reaction Methods 0.000 description 1
- 229940124597 therapeutic agent Drugs 0.000 description 1
- DSNBHJFQCNUKMA-SCKDECHMSA-N thromboxane A2 Chemical compound OC(=O)CCC\C=C/C[C@@H]1[C@@H](/C=C/[C@@H](O)CCCCC)O[C@@H]2O[C@H]1C2 DSNBHJFQCNUKMA-SCKDECHMSA-N 0.000 description 1
- 210000001519 tissue Anatomy 0.000 description 1
- 239000003440 toxic substance Substances 0.000 description 1
- 102000003390 tumor necrosis factor Human genes 0.000 description 1
- 239000002550 vasoactive agent Substances 0.000 description 1
- 230000002227 vasoactive effect Effects 0.000 description 1
- 239000011782 vitamin Substances 0.000 description 1
- 235000013343 vitamin Nutrition 0.000 description 1
- 229940088594 vitamin Drugs 0.000 description 1
- 229930003231 vitamin Natural products 0.000 description 1
- 238000005406 washing Methods 0.000 description 1
- 238000009736 wetting Methods 0.000 description 1
Images
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
- A61M1/00—Suction or pumping devices for medical purposes; Devices for carrying-off, for treatment of, or for carrying-over, body-liquids; Drainage systems
- A61M1/34—Filtering material out of the blood by passing it through a membrane, i.e. hemofiltration or diafiltration
- A61M1/3472—Filtering material out of the blood by passing it through a membrane, i.e. hemofiltration or diafiltration with treatment of the filtrate
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
- A61M1/00—Suction or pumping devices for medical purposes; Devices for carrying-off, for treatment of, or for carrying-over, body-liquids; Drainage systems
- A61M1/34—Filtering material out of the blood by passing it through a membrane, i.e. hemofiltration or diafiltration
- A61M1/3472—Filtering material out of the blood by passing it through a membrane, i.e. hemofiltration or diafiltration with treatment of the filtrate
- A61M1/3479—Filtering material out of the blood by passing it through a membrane, i.e. hemofiltration or diafiltration with treatment of the filtrate by dialysing the filtrate
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
- A61M1/00—Suction or pumping devices for medical purposes; Devices for carrying-off, for treatment of, or for carrying-over, body-liquids; Drainage systems
- A61M1/34—Filtering material out of the blood by passing it through a membrane, i.e. hemofiltration or diafiltration
- A61M1/3472—Filtering material out of the blood by passing it through a membrane, i.e. hemofiltration or diafiltration with treatment of the filtrate
- A61M1/3482—Filtering material out of the blood by passing it through a membrane, i.e. hemofiltration or diafiltration with treatment of the filtrate by filtrating the filtrate using another cross-flow filter, e.g. a membrane filter
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
- A61M1/00—Suction or pumping devices for medical purposes; Devices for carrying-off, for treatment of, or for carrying-over, body-liquids; Drainage systems
- A61M1/34—Filtering material out of the blood by passing it through a membrane, i.e. hemofiltration or diafiltration
- A61M1/3472—Filtering material out of the blood by passing it through a membrane, i.e. hemofiltration or diafiltration with treatment of the filtrate
- A61M1/3486—Biological, chemical treatment, e.g. chemical precipitation; treatment by absorbents
Landscapes
- Health & Medical Sciences (AREA)
- Heart & Thoracic Surgery (AREA)
- Biomedical Technology (AREA)
- Engineering & Computer Science (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Hematology (AREA)
- Anesthesiology (AREA)
- Vascular Medicine (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Biodiversity & Conservation Biology (AREA)
- Cell Biology (AREA)
- Molecular Biology (AREA)
- External Artificial Organs (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US86250806P | 2006-10-23 | 2006-10-23 | |
| PCT/US2007/082268 WO2008051994A2 (en) | 2006-10-23 | 2007-10-23 | Fluid-conserving cascade hemofiltration |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2010507464A true JP2010507464A (ja) | 2010-03-11 |
| JP2010507464A5 JP2010507464A5 (enExample) | 2010-12-16 |
Family
ID=39284248
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2009534821A Pending JP2010507464A (ja) | 2006-10-23 | 2007-10-23 | 液体節約型カスケード血液濾過法 |
Country Status (3)
| Country | Link |
|---|---|
| EP (1) | EP2076297A2 (enExample) |
| JP (1) | JP2010507464A (enExample) |
| WO (1) | WO2008051994A2 (enExample) |
Families Citing this family (17)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP2606921A1 (fr) * | 2011-12-21 | 2013-06-26 | Infomed SA | Dispositif d'épuration du sang par circulation extracorporelle |
| EP2800592B1 (en) * | 2012-01-04 | 2019-03-06 | Medtronic Inc. | Multi-staged filtration system for blood fluid removal |
| DE102012025164A1 (de) * | 2012-12-21 | 2014-06-26 | Fresenius Medical Care Deutschland Gmbh | Vorrichtung zur Entfernung proteingebundener Toxine aus Blutplasma |
| US10010663B2 (en) | 2013-02-01 | 2018-07-03 | Medtronic, Inc. | Fluid circuit for delivery of renal replacement therapies |
| US9623164B2 (en) | 2013-02-01 | 2017-04-18 | Medtronic, Inc. | Systems and methods for multifunctional volumetric fluid control |
| US10850016B2 (en) | 2013-02-01 | 2020-12-01 | Medtronic, Inc. | Modular fluid therapy system having jumpered flow paths and systems and methods for cleaning and disinfection |
| US9144640B2 (en) | 2013-02-02 | 2015-09-29 | Medtronic, Inc. | Sorbent cartridge configurations for improved dialysate regeneration |
| ITMI20131250A1 (it) * | 2013-07-25 | 2015-01-25 | Warsaw Medical University | Blood purification systems and devices with internally generated replacement fluid |
| ES2727153T3 (es) * | 2014-04-17 | 2019-10-14 | Immutrix Therapeutics Inc | Composiciones de destoxificación terapéutica y métodos para la preparación y utilización de las mismas |
| US9713665B2 (en) | 2014-12-10 | 2017-07-25 | Medtronic, Inc. | Degassing system for dialysis |
| US10874787B2 (en) | 2014-12-10 | 2020-12-29 | Medtronic, Inc. | Degassing system for dialysis |
| US10098993B2 (en) | 2014-12-10 | 2018-10-16 | Medtronic, Inc. | Sensing and storage system for fluid balance |
| US11278654B2 (en) | 2017-12-07 | 2022-03-22 | Medtronic, Inc. | Pneumatic manifold for a dialysis system |
| CN108211032B (zh) | 2018-02-01 | 2023-11-17 | 南方医科大学珠江医院 | 组合型生物人工肝支持系统 |
| US11033667B2 (en) | 2018-02-02 | 2021-06-15 | Medtronic, Inc. | Sorbent manifold for a dialysis system |
| US11110215B2 (en) | 2018-02-23 | 2021-09-07 | Medtronic, Inc. | Degasser and vent manifolds for dialysis |
| US12128165B2 (en) | 2020-04-27 | 2024-10-29 | Mozarc Medical Us Llc | Dual stage degasser |
Citations (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO1984000112A1 (en) * | 1982-06-23 | 1984-01-19 | Nor Tron As | Apparatus for separating from a biological liquid, in particular blood, a fraction having molecular weight between an upper and lower limiting value |
| JPS62258672A (ja) * | 1986-02-10 | 1987-11-11 | ミリポア・コ−ポレイシヨン | 透析濾過装置及び方法 |
| JPS63212368A (ja) * | 1986-11-26 | 1988-09-05 | ファビオ ファスティング バイオテック アクチーセルスカペット | クリオグロブリン除去デバイス |
Family Cites Families (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AU2069695A (en) * | 1995-03-13 | 1996-10-02 | Ao Forschungsinstitut Davos | An extracorporeal blood treatment apparatus and method for removal of free circulating infectious agents |
| US6193681B1 (en) * | 1998-09-14 | 2001-02-27 | American Immuno Tech, Llc. | Septicemia prevention and treatment system |
| ITPD20030076A1 (it) * | 2003-04-16 | 2003-07-15 | Federico Nalesso | Macchina per plasma purificazione combinata a plasma adsorbimento-perfusione mediante utilizzo di dializzatore tricompartimentale |
-
2007
- 2007-10-23 WO PCT/US2007/082268 patent/WO2008051994A2/en not_active Ceased
- 2007-10-23 JP JP2009534821A patent/JP2010507464A/ja active Pending
- 2007-10-23 EP EP07854348A patent/EP2076297A2/en not_active Withdrawn
Patent Citations (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO1984000112A1 (en) * | 1982-06-23 | 1984-01-19 | Nor Tron As | Apparatus for separating from a biological liquid, in particular blood, a fraction having molecular weight between an upper and lower limiting value |
| JPS62258672A (ja) * | 1986-02-10 | 1987-11-11 | ミリポア・コ−ポレイシヨン | 透析濾過装置及び方法 |
| JPS63212368A (ja) * | 1986-11-26 | 1988-09-05 | ファビオ ファスティング バイオテック アクチーセルスカペット | クリオグロブリン除去デバイス |
Also Published As
| Publication number | Publication date |
|---|---|
| WO2008051994A2 (en) | 2008-05-02 |
| EP2076297A2 (en) | 2009-07-08 |
| WO2008051994A3 (en) | 2008-07-10 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2010507464A (ja) | 液体節約型カスケード血液濾過法 | |
| US11596901B2 (en) | Biomimetically designed modular microfluidic-based capillaries and lymphatic units for kidney and liver dialysis systems, organ bio-reactors and bio-artificial organ support systems | |
| US9713668B2 (en) | Multi-staged filtration system for blood fluid removal | |
| CN100502959C (zh) | 用于除去部分蛋白质结合物质的方法和装置 | |
| US8038638B2 (en) | Plasma detoxification and volume control system and methods of use | |
| US8414772B2 (en) | Method for differentiation of substances | |
| US20130102948A1 (en) | Portable blood filtration devices, systems, and methods | |
| EP1765433B1 (en) | Plasma detoxification and volume control system | |
| JP2005535394A (ja) | 選択的血漿交換方法 | |
| WO2016205221A1 (en) | System and method for extracorporeal blood treatment | |
| Santoro et al. | Prometheus system: a technological support in liver failure | |
| US9950103B2 (en) | Combination kidney and liver dialysis system and method | |
| CA2759744C (en) | Dialysis device | |
| EP3563888A1 (en) | Multi-stage blood purification apparatus for removal of toxins | |
| US20230036583A1 (en) | Devices and methods for reducing rejection of a transplanted organ in a recipient | |
| de Francisco et al. | Hemodiafiltration with on-line endogenous reinfusion | |
| US20170266362A1 (en) | System for removal of pro-inflammatory mediators as well as granulocytes and monocytes from blood | |
| US9333285B2 (en) | Method and device for downgrading at least one component of a fluid medium | |
| WO2015011290A1 (en) | Blood purification systems and devices with internally generated replacement fluid | |
| Di Paola | Artificial kidney: a chemical engineering challenge | |
| Nosé et al. | Hepatic Assist 2: Devices for Use with Sorbents and Biological Reactors | |
| Greenwood | The machine and the therapy concept | |
| Varley | Renal Replacement Therapy | |
| Kim et al. | -Extracorporeal Blood-Filtering Technologies |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20101025 |
|
| A621 | Written request for application examination |
Free format text: JAPANESE INTERMEDIATE CODE: A621 Effective date: 20101025 |
|
| A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20111025 |
|
| A977 | Report on retrieval |
Free format text: JAPANESE INTERMEDIATE CODE: A971007 Effective date: 20120827 |
|
| A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20120830 |
|
| A601 | Written request for extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A601 Effective date: 20121129 |
|
| A602 | Written permission of extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A602 Effective date: 20121206 |
|
| A02 | Decision of refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A02 Effective date: 20130501 |